A microfluidic chip developed at the University of Michigan is among the best at capturing elusive circulating tumor cells from blood—and it can support the cells’ growth for further analysis.
The device, believed to be the first to pair these functions, uses the advanced electronics material graphene oxide. In clinics, such a device could one day help doctors diagnose cancers, give more accurate prognoses and test treatment options on cultured cells without subjecting patients to traditional biopsies.
“If we can get these technologies to work, it will advance new cancer drugs and revolutionize the treatment of cancer patients,” said Max Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center and co-author of a paper on the new device, published online this week in Nature Nanotechnology.
“Circulating tumor cells will play a significant role in the early diagnosis of cancer and to help us understand if treatments are working in our cancer patients by serving as a ‘liquid’ biopsy to assess treatment responses in real time,” said co-author Dr. Diane Simeone, the Lazar J. Greenfield Professor of Surgery at the U-M Medical School and director of the Translational Oncology Program.
“Studies of circulating tumor cells will also help us understand the basic biologic mechanisms by which cancer cells metastasize or spread to distant organs—the major cause of death in cancer patients.”
Yet these cells aren’t living up to their promise in medicine because they are so difficult to separate from a blood sample, the researchers say. In the blood of early-stage cancer patients, they account for less than one in every billion cells, so catching them is tougher than finding the proverbial needle in a haystack.
“I can burn the haystack or use a huge magnet,” said Sunitha Nagrath, an assistant professor of chemical engineering, who led the research. “When it comes to circulating tumor cells, they almost look like—feel like—any other blood cell.”
On their microfluidic chip, Nagrath’s team grew dense forests of molecular chains, each equipped with an antibody to grab onto cancer cells.
Even after the cells are caught, it’s still hard to run a robust analysis on just a handful of them, the researchers say. That’s why this demonstration of highly sensitive tumor cell capture, combined with the ability to grow the cells in the same device, is so promising.
Hyeun Joong Yoon, a postdoctoral researcher in the Nagrath lab with a background in electrical engineering, was instrumental in making the microfluidic chip. He started with a silicon base and added a grid of nearly 60,000 flat gold shapes, like four-petaled flowers, each no wider than a strand of hair.
The gold flowers naturally attracted a relatively new material called graphene oxide. These sheets of carbon and oxygen, just a few atoms thick, layered themselves over the gold. This layered formation allowed the team to grow the tumor-cell-catching molecular chains so densely.
“It’s almost like each graphene has many nano-arms to capture cells,” Nagrath said.
To test the device, the team ran one-milliliter samples of blood through the chip’s thin chamber. Even when they had added just three-to-five cancer cells to the 5-10 billion blood cells, the chip was able to capture all of the cells in the sample half the time, with an average of 73 percent over 10 trials.
“That’s the highest anybody has shown in the literature for spiking such a low number of cells,” Nagrath said.
The Latest on: Liquid biopsy
- Advance Study on Liquid Biopsy with Emphasis on Cancer Market by Top Key Players 2023: ALCEDIAG, ANGLE PLC, ACCURAGEN INC., BIOCEPT INC.on June 21, 2019 at 3:11 pm
The study methodologies used to examine the Liquid Biopsy with Emphasis on Cancer market for the forecast period, 2018 - 2023 further classifies the industry by type, geography, end-use and end-user ... […]
- Insights Into the World Fluid Biopsy Market (2019-2024): Breast Cancer Expected to Grow with a High CAGRon June 21, 2019 at 7:33 am
Breast biopsy test removes tissue or sometimes fluid from the suspicious area, and the removed cells are examined under a microscope and further tested, to check for the presence of breast cancer. ... […]
- Angle PLC Announces Parsortix Used to Investigate Immunotherapy Targeton June 20, 2019 at 11:02 pm
June 21, 2019 (ACCESSWIRE via COMTEX) -- Leading Cancer Centre Demonstrates Use of Parsortix as a Liquid Biopsy to Investigate Key Immunotherapy Target in Lung Cancer Potential for use of Parsortix as ... […]
- Questions about liquid biopsy & the latest longevity debateon June 19, 2019 at 5:10 pm
Damian covers biotech and writes The Readout newsletter. We were inspired to become primary care physicians. Now… We were inspired to become primary care physicians. Now we’re reconsidering a field in ... […]
- Two Stocks Making Advances in Oncologyon June 19, 2019 at 2:02 am
Its liquid biopsy tests are used in both biopharma (GuardantOMNI covers 500 genes) and clinical (Guardant360 covers 73 genes) use cases. It has an addressable market of around $10 billion today, but ... […]
- Global Liquid Biopsy Markets to 2023 with Emphasis on Canceron June 17, 2019 at 3:50 am
Dublin, June 17, 2019 (GLOBE NEWSWIRE) -- The "Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023" report has been added to ResearchAndMarkets.com's offering. The scope of the report ... […]
- Zomedica Announces Completion of Initial Development of a Lymphoma Assay for its Canine Cancer Liquid Biopsy Platformon June 13, 2019 at 5:00 pm
ANN ARBOR, Mich., June 13, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM), a veterinary diagnostic and pharmaceutical company, today announced that it has ... […]
- Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023on June 13, 2019 at 1:58 pm
NEW YORK, June 13, 2019 /PRNewswire/ -- Report Scope: The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding ... […]
- Skinflow: A Soft Robotic Skin Based on Liquid Transmissionon June 13, 2019 at 12:49 pm
Using sound vibrations and pulses of near-infrared light, a Rutgers University scientist has developed a new "virtual biopsy" device that can quickly determine a skin lesion's depth and potential ... […]
- Liquid Biopsy Test to Find All Cancers Is Out of Reach for 2019on June 7, 2019 at 5:12 am
What if a simple blood test could tell if you had cancer? Grail Inc. -- founded by Illumina Inc. and backed by both Jeff Bezos and Bill Gates -- has been targeting just that, but after some early hype ... […]
via Google News and Bing News